CRRTF (Crescita Therapeutics) Cyclically Adjusted Revenue per Share: $0.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRRTF Crescita Therapeutics Inc CRRTF
22 GF Score
Price $0.56
GF Value $0.50
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Cyclically Adjusted Revenue per Share?

Crescita Therapeutics CRRTF 22 Cyclically Adjusted Revenue per Share is $0.74 as of Mar. 2026. GuruFocus rates CRRTF with a GF Score™ of 22/100 and a GF Value™ of $0.50 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Crescita Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was $0.221. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Crescita Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-04), Crescita Therapeutics's current stock price is $0.5587. Crescita Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.74. Crescita Therapeutics's Cyclically Adjusted PS Ratio of today is 0.76.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Crescita Therapeutics was 0.77. The lowest was 0.46. And the median was 0.60.


Crescita Therapeutics  (OTCPK:CRRTF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Crescita Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.5587/0.74
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Crescita Therapeutics was 0.77. The lowest was 0.46. And the median was 0.60.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Crescita Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Crescita Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Cyclically Adjusted Revenue per Share Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.66 0.70

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.44 0.68 0.70 0.74

CRRTF vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Cyclically Adjusted PS Ratio falls into.


CRRTF
22GF Score
Crescita Therapeutics Inc CRRTF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Crescita Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.221/132.2623*132.2623
=0.221

Current CPI (Mar. 2026) = 132.2623.

Crescita Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.006 102.002 0.008
201609 0.056 101.765 0.073
201612 0.131 101.449 0.171
201703 0.112 102.634 0.144
201706 0.262 103.029 0.336
201709 0.158 103.345 0.202
201712 0.132 103.345 0.169
201803 0.180 105.004 0.227
201806 0.084 105.557 0.105
201809 0.163 105.636 0.204
201812 0.220 105.399 0.276
201903 0.151 106.979 0.187
201906 0.313 107.690 0.384
201909 0.163 107.611 0.200
201912 0.128 107.769 0.157
202003 0.132 107.927 0.162
202006 0.062 108.401 0.076
202009 0.253 108.164 0.309
202012 0.106 108.559 0.129
202103 0.126 110.298 0.151
202106 0.117 111.720 0.139
202109 0.114 112.905 0.134
202112 0.281 113.774 0.327
202203 0.187 117.646 0.210
202206 0.244 120.806 0.267
202209 0.216 120.648 0.237
202212 0.205 120.964 0.224
202303 0.165 122.702 0.178
202306 0.191 124.203 0.203
202309 0.110 125.230 0.116
202312 0.176 125.072 0.186
202403 0.188 126.258 0.197
202406 0.153 127.522 0.159
202409 0.138 127.285 0.143
202412 0.253 127.364 0.263
202503 0.129 129.181 0.132
202506 0.240 129.892 0.244
202509 0.207 130.287 0.210
202512 0.232 130.366 0.235
202603 0.221 132.262 0.221

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.74 mean?
Crescita Therapeutics (CRRTF) has a Cyclically Adjusted Revenue per Share of $0.74 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Cyclically Adjusted Revenue per Share too high?
Crescita Therapeutics' current Cyclically Adjusted Revenue per Share is $0.74. Overall, Crescita Therapeutics has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Cyclically Adjusted Revenue per Share compare to ZTS?
Crescita Therapeutics' Cyclically Adjusted Revenue per Share of $0.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Cyclically Adjusted Revenue per Share is $0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (CRRTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.50, compared to a current price of $0.56 — trading 11.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.74. Crescita Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Crescita Therapeutics (CRRTF), the current Cyclically Adjusted Revenue per Share is $0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crescita Therapeutics (CRRTF) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of $0.56 is trading 11.7% above its estimated GF Value™ of $0.50. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for CRRTF:

  • Cyclically Adjusted Revenue per Share: $0.74
  • GF Value™: $0.50 vs. price of $0.56 (11.7% above fair value)
  • GF Score™: 22/100 with 5 warning signs

No single metric tells the full story. See the CRRTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
22GF Score

Get the complete analysis for CRRTF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.50
GF Value